Additional US platform programme account

RNS Number : 4870Q

Deltex Medical Group PLC

30 November 2016

 

30 November 2016

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Additional US platform programme account

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added a new account to its platform programme in the USA.

The hospital, in the North-East, is a Level 1 Trauma Center of over 400 beds and one of the longest established teaching hospitals in the country. The hospital's plan is to start implementation in December 2016 with a small group of doctors aiming to treat 30 patients a month before expanding the number of doctors and range of procedures.

The new hospital is the 28^th US platform programme account and the 6^th  in the North-East territory.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"Our business in the USA, our main focus market, continues to expand with growth rates ahead of other countries. In a number of our territories, including the North-East, we have now established a regional platform of large accounts with substantial potential for future growth."

For further information, please contact:-

Deltex Medical Group plc	01243 774 837 [e-mail]
Nigel Keen, Chairman
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director Barry Curtis, Company Secretary
Nominated Adviser & Broker
Arden Partners plc	020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory	0203 053 8671
Tim Metcalfe Graham Herring Heather Armstrong

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

 

END

 

 

NRAWGGUUGUPQUUU